Sugi Predict

Sugi Predict / Compounds / SCHEMBL1997846

SCHEMBL1997846

SCHEMBL1997846

COc1cccc(C(=O)O)c1Br

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ HTT P42858 1/20 0.58
▸ CA12 O43570 2/20 0.57
▸ CA1 P00915 2/20 0.57
▸ CA2 P00918 2/20 0.57
▸ CA7 P43166 2/20 0.57
▸ CA9 Q16790 2/20 0.57
▸ CA14 Q9ULX7 2/20 0.57
▸ KDM4E B2RXH2 6/20 0.56
▸ HPGD P15428 5/20 0.56
▸ ALDH1A1 P00352 4/20 0.56
▸ HSD17B10 Q99714 3/20 0.56
▸ LCK P06239 1/20 0.52
▸ FYN P06241 1/20 0.52
▸ KMT2A Q03164 1/20 0.50
▸ FABP3 P05413 1/20 0.49
▸ FABP4 P15090 1/20 0.49
▸ FABP5 Q01469 1/20 0.49
▸ MAPK1 P28482 1/20 0.47
▸ TDP1 Q9NUW8 2/20 0.47
▸ ESR1 P03372 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1287120 0.85 LMNA (0.51) HTTCA12CA1CA2CA7
SCHEMBL2430627 0.83 GAA (0.53) HTTCA12CA1CA2CA7
SCHEMBL5424186 0.83 CTSD (0.47) HTTCA12CA1CA2CA7
SCHEMBL9336432 0.82 ALDH1A1 (0.44) HTTCA12CA1CA2CA7
SCHEMBL6648374 0.82 MAPT (0.55) HTTCA12CA1CA2CA7
SCHEMBL6691622 0.81 KDM4E (0.68) HTTKDM4EHPGDALDH1A1HSD17B10
SCHEMBL7113203 0.81 CDC25B (0.55) HTTCA12CA1CA2CA7
SCHEMBL27465671 0.80 TSHR (0.56) HTTKDM4EALDH1A1HSD17B10KMT2A
SCHEMBL7783864 0.80 HPGDS (0.55) HTTCA12CA1CA2CA7
SCHEMBL27624489 0.80 HMGCR (0.49) HTTCA12CA1CA2CA7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 77 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260028316-A1 Biphenyl and Phenylpyridine Compounds PFIZER INC. (US) 2026-01-29 — — US disclosed
US-20250188030-A1 Biphenyl and Phenylpyridine Compounds PFIZER INC. (US) 2025-06-12 — — US disclosed
US-20230364079-A1 COMPOUND AS BRAIN-PERMEABLE BTK OR HER2 INHIBITOR, PREPARATION METHOD THEREFOR, AND USE THEREOF CHENGDU HYPERWAY PHARMACEUTICALS CO., LTD. (CN) 2023-11-16 — — US disclosed
EP-3860975-B1 MODULATORS OF HEMOGLOBIN FOR THE TREATMENT OF SICKLE CELL DISEASE GLOBAL BLOOD THERAPEUTICS INC (US) 2023-10-18 — — EP disclosed
EP-3860975-B1 MODULATORS OF HEMOGLOBIN FOR THE TREATMENT OF SICKLE CELL DISEASE GLOBAL BLOOD THERAPEUTICS INC (US) 2023-10-18 — — EP disclosed
US-20230257383-A1 COMPOUND SERVING AS BTK INHIBITOR, PREPARATION METHOD THEREFOR, AND USE THEREOF CHENGDU HYPERWAY PHARMACEUTICALS CO., LTD. (CN) 2023-08-17 — — US disclosed
US-20230257383-A1 COMPOUND SERVING AS BTK INHIBITOR, PREPARATION METHOD THEREFOR, AND USE THEREOF CHENGDU HYPERWAY PHARMACEUTICALS CO., LTD. (CN) 2023-08-17 — — US disclosed
US-20230192622-A1 ANTI-SARS-COV-2 DRUG ONCOLYS BIOPHARMA, INC. (JP) 2023-06-22 — — US disclosed
EP-4186906-A1 COMPOUND AS BRAIN-PERMEABLE BTK OR HER2 INHIBITOR, PREPARATION METHOD THEREFOR, AND USE THEREOF Chengdu Hyperway Pharmaceuticals Co., Ltd. (CN) 2023-05-31 — — EP disclosed
EP-4154884-A1 ANTI-SARS-COV-2 DURG Oncolys BioPharma, Inc. (JP) 2023-03-29 — — EP disclosed
US-20090163471-A1 Tropane compounds EXELIXIS, INC. 2009-06-25 — — US disclosed
US-20090163471-A1 Tropane compounds EXELIXIS, INC. 2009-06-25 — — US disclosed
WO-2009055077-A1 TROPANE COMPOUNDS EXELIXIS, INC. (US) 2009-04-30 — — WO disclosed
EP-1795527-B1 CARBAMOYL-SUBSTITUTED SPIRO DERIVATIVE BANYU PHARMA CO LTD (JP) 2009-04-22 — — EP disclosed
US-20080171753-A1 Carbamoyl-Substituted Spiro Derivative MSD K.K. (JP) 2008-07-17 — — US disclosed
US-7312209-B2 Acridone inhibitors of IMPDH enzyme BRISTOL-MYERS SQUIBB COMPANY (US) 2007-12-25 — — US disclosed
CN-101056861-A Carbamoyl-substituted spiro derivatives BANYU PHARMA CO LTD (JP) 2007-10-17 — — CN disclosed
EP-1795527-A1 CARBAMOYL-SUBSTITUTED SPIRO DERIVATIVE BANYU PHARMACEUTICAL CO., LTD. (JP) 2007-06-13 — — EP disclosed
CN-1136198-C Novel benzyl pyrimidines ��������ҩ�ɷ����޹�˾ 2004-01-28 — — CN disclosed
CN-1166831-A Novel benzyl pyrimidines HOFFMANN LA ROCHE (CH) 1997-12-03 — — CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250188030-A1 Biphenyl and Phenylpyridine Compounds CYP1B1, CYP1A1, PAH HTT 785/4885CA12 4556/4885CA1 4296/4885
US-20230192622-A1 ANTI-SARS-COV-2 DRUG ACE2, ACE, SARS1 HTT 736/4885CA12 1337/4885CA1 4223/4885
US-20090163471-A1 Tropane compounds ADRA1B, ADRA2B, ADRB2 HTT 1328/4885CA12 2176/4885CA1 3528/4885
US-20260028316-A1 Biphenyl and Phenylpyridine Compounds KAT2B, KAT2A, KAT6A HTT 305/4885CA12 3995/4885CA1 4083/4885
US-20080171753-A1 Carbamoyl-Substituted Spiro Derivative HRH3, HRH4, HRH2 HTT 237/4885CA12 2875/4885CA1 1242/4885
US-20230257383-A1 COMPOUND SERVING AS BTK INHIBITOR, PREPARATION METHOD THEREFOR, AND USE THEREOF BTK, WEE1, WEE2 HTT 3786/4885CA12 4638/4885CA1 4256/4885
US-20230364079-A1 COMPOUND AS BRAIN-PERMEABLE BTK OR HER2 INHIBITOR, PREPARATION METHOD THEREFOR, AND USE THEREOF BTK, WEE2, WEE1 HTT 1352/4885CA12 2303/4885CA1 1289/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.